Simon J C Davies1,2, Benoit H Mulsant3,4, Alastair J Flint4,5, Barnett S Meyers6, Anthony J Rothschild7, Ellen M Whyte8, Margaret M Kirshner9, Denise Sorisio8, Bruce G Pollock3,4, Robert R Bies3,10,11. 1. Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, ON, M6J 1H4, Canada. simon_davies@camh.net. 2. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. simon_davies@camh.net. 3. Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, ON, M6J 1H4, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 5. Department of Psychiatry, University Health Network, Toronto, ON, Canada. 6. Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA. 7. University of Massachusetts Medical School and University of Massachusetts Memorial Health Care, Worcester, MA, USA. 8. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 9. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 10. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. 11. Indiana Clinical and Translational Sciences Institute, Indianapolis, IN, USA.
Abstract
BACKGROUND AND OBJECTIVE: Clinical evidence and expert opinion support using a combination of an antipsychotic and an antidepressant when treating major depression with psychotic features. We characterized the impact of sertraline co-administration on olanzapine clearance in psychotic depression using population pharmacokinetic methods. METHODS: The Study of Pharmacotherapy for Psychotic Depression (STOP-PD) randomized 259 participants to olanzapine plus placebo or olanzapine plus sertraline. Olanzapine was started at 2.5-5 mg/day and sertraline at 25-50 mg/day. Doses were increased to a maximum of 20 mg/day for olanzapine and 200 mg/day for sertraline. Up to four olanzapine concentration samples were collected during the 12-week trial and 12-week continuation phase. We used NONMEM (Version VII) for population pharmacokinetic analysis, assessing effects of the covariates sex, African American origin, smoking, age, and sertraline co-administration. RESULTS: Population pharmacokinetic analysis comprised 336 samples from 175 individuals. The structural model published by Bigos et al. was sufficient to describe the olanzapine data adequately: a one-compartment model with first-order absorption and elimination, using an additive residual error structure with the absorption rate constant fixed to 0.5. Sertraline co-administration significantly increased olanzapine apparent clearance (p < 0.005) by 25-35 % depending on the patient characteristics included. Male sex was associated with a significantly increased clearance. Age and race did not have a significant impact on clearance. CONCLUSIONS: Contrary to expectations from the knowledge of cytochrome P450 interactions, sertraline increased olanzapine apparent clearance. Plausible explanations include patients treated with sertraline having poorer adherence to olanzapine, or the impact of sertraline inhibition of transporters resulting in increased intracellular concentrations and thus access to metabolizing enzymes.
RCT Entities:
BACKGROUND AND OBJECTIVE: Clinical evidence and expert opinion support using a combination of an antipsychotic and an antidepressant when treating major depression with psychotic features. We characterized the impact of sertraline co-administration on olanzapine clearance in psychotic depression using population pharmacokinetic methods. METHODS: The Study of Pharmacotherapy for Psychotic Depression (STOP-PD) randomized 259 participants to olanzapine plus placebo or olanzapine plus sertraline. Olanzapine was started at 2.5-5 mg/day and sertraline at 25-50 mg/day. Doses were increased to a maximum of 20 mg/day for olanzapine and 200 mg/day for sertraline. Up to four olanzapine concentration samples were collected during the 12-week trial and 12-week continuation phase. We used NONMEM (Version VII) for population pharmacokinetic analysis, assessing effects of the covariates sex, African American origin, smoking, age, and sertraline co-administration. RESULTS: Population pharmacokinetic analysis comprised 336 samples from 175 individuals. The structural model published by Bigos et al. was sufficient to describe the olanzapine data adequately: a one-compartment model with first-order absorption and elimination, using an additive residual error structure with the absorption rate constant fixed to 0.5. Sertraline co-administration significantly increased olanzapine apparent clearance (p < 0.005) by 25-35 % depending on the patient characteristics included. Male sex was associated with a significantly increased clearance. Age and race did not have a significant impact on clearance. CONCLUSIONS: Contrary to expectations from the knowledge of cytochrome P450 interactions, sertraline increased olanzapine apparent clearance. Plausible explanations include patients treated with sertraline having poorer adherence to olanzapine, or the impact of sertraline inhibition of transporters resulting in increased intracellular concentrations and thus access to metabolizing enzymes.
Authors: Barnett S Meyers; Alastair J Flint; Anthony J Rothschild; Benoit H Mulsant; Ellen M Whyte; Catherine Peasley-Miklus; Eros Papademetriou; Andrew C Leon; Moonseong Heo Journal: Arch Gen Psychiatry Date: 2009-08
Authors: Lindsey I Sinclair; David M Christmas; Sean D Hood; John P Potokar; Andrea Robertson; Andrew Isaac; Shrikant Srivastava; David J Nutt; Simon J C Davies Journal: Br J Psychiatry Date: 2009-06 Impact factor: 9.319
Authors: Maxine X Patel; Sally Bowskill; Lewis Couchman; Victoria Lay; David Taylor; Edgar Pathrose Spencer; Robert James Flanagan Journal: J Clin Psychopharmacol Date: 2011-08 Impact factor: 3.153
Authors: Amita Kapoor; Majid Iqbal; Sophie Petropoulos; Hay Lam Ho; William Gibb; Stephen G Matthews Journal: PLoS One Date: 2013-02-28 Impact factor: 3.240
Authors: Thomas M Polasek; Geoffrey T Tucker; Michael J Sorich; Michael D Wiese; Titus Mohan; Amin Rostami-Hodjegan; Porntipa Korprasertthaworn; Vidya Perera; Andrew Rowland Journal: Br J Clin Pharmacol Date: 2018-01-11 Impact factor: 4.335
Authors: Rachel Huddart; J Kevin Hicks; Laura B Ramsey; Jeffrey R Strawn; D Max Smith; Margarita Bobonis Babilonia; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2020-02 Impact factor: 2.000
Authors: Anil R Maharaj; Huali Wu; Kanecia O Zimmerman; Julie Autmizguine; Rohit Kalra; Amira Al-Uzri; Catherine M T Sherwin; Stuart L Goldstein; Kevin Watt; Jinson Erinjeri; Elizabeth H Payne; Michael Cohen-Wolkowiez; Christoph P Hornik Journal: Br J Clin Pharmacol Date: 2020-07-05 Impact factor: 3.716